Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 55-67

  Kłossowski, Szymon ^a   Muchowicz, Angelika ^b   Firczuk, Małgorzata ^b   Świech, Marta ^b   Redzej, Adam ^a   Golab, Jakub ^b   Ostaszewski, Ryszard ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 BISTRIFLUOROMETHYLBENZOIC ACID 2 [1 (ETHOXYCARBONYLMETHYLCARBAMOYL) 3 METHYLBUTYLCARBAMOYL]ALLYL ESTER; 2,6 DICHLOROBENZOIC ACID 2 [1 (ETHOXYCARBONYLMETHYLCARBAMOYL) 3 METHYLBUTYLCARBAMOYL]ALLYL ESTER; [2 (2 BROMOMETHYLACRYLOYLAMINO) 4 METHYLPENTANOYLAMINO]; [2 (2 BROMOMETHYLACRYLOYLAMINO) 4 METHYLPENTANOYLAMINO]ACETIC ACID ETHYL ESTER; [2 [BENZYL (2 BROMOMETHYLACRYLOYL)AMINO] 4 METHYLPENTANOYLAMINO]ACETIC ACID BENZYL ESTER; [2 [BENZYL (2 IODOMETHYLACRYLOYL)AMINO] 4 METHYLPENTANOYLAMINO]ACETIC ACID BENZYL ESTER; [2 [BENZYL (3 BROMO 2 BROMOMETHYLPROPIONYL)AMINO] 4 METHYLPENTANOYLAMINO]ACETIC ACID BENZYL ESTER; [2 [BENZYL (3 IODO 2 IODOMETHYLPROPIONYL)AMINO] 4 METHYLPENTANOYLAMINO]ACETIC ACID BENZYL ESTER; [2 [BENZYL (3 METHANESULFONYLOXY 2 METHANESULFONYLOXYMETHYLPROPIONYL)AMINO] 4 METHYL PENTANOYLAMINO]ACETIC ACID BENZYL ESTER; [2 [BENZYL [3 (TOLUENE 4 SULFONYLOXY) 2 (TOLUENE 4 SULFONYLOXYMETHYL)PROPIONYL]AMINO] 4 METHYLPENTANOYLAMINO]ACETIC ACID BENZYL ESTER; ANTINEOPLASTIC AGENT; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDOMIMETIC AGENT; SK 053; THIOREDOXIN; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DRUG SYNTHESIS; ELECTROPHILICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; SYNTHETIC BIOLOGY; THIOREDOXIN THIOREDOXIN REDUCTASE SYSTEM; TUMOR CELL; UGI REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXINS; DIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; FREE RADICAL SCAVENGERS; HUMANS; HYDROGEN PEROXIDE; METHACRYLATES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PEPTIDOMIMETICS; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS; TRANSCRIPTION FACTOR AP-1; TRANSPLANTATION, HETEROLOGOUS;

EID: 84855835527     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201359d     Document Type: Article

References (52)

1. Wu, C.; Parrott, A. M.; Fu, C.; Liu, T.; Marino, S. M.; Gladyshev, V. N.; Jain, M. R.; Baykal, A. T.; Li, Q.; Oka, S.; Sadoshima, J.; Beuve, A.; Simmons, W. J.; Li, H. Thioredoxin 1-mediated post-translational modifications: Reduction, transnitrosylation, denitrosylation, and related proteomics methodologies Antioxid. Redox Signaling 2011, 15, 2565-2604
2. Ueno, M.; Masutani, H.; Arai, R. J.; Yamauchi, A.; Hirota, K.; Sakai, T.; Inamoto, T.; Yamaoka, Y.; Yodoi, J.; Nikaido, T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation J. Biol. Chem. 1999, 274, 35809-35815
3. Tonissen, K. F.; Di Trapani, G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy Mol. Nutr. Food Res. 2009, 53, 87-103
4. Powis, G.; Montfort, W. R. Properties and biological activities of thioredoxins Annu. Rev. Pharmacol. Toxicol. 2001, 41, 261-295
5. Lee, S. R.; Yang, K. S.; Kwon, J.; Lee, C.; Jeong, W.; Rhee, S. G. Reversible inactivation of the tumor suppressor PTEN by H2O2 J. Biol. Chem. 2002, 277, 20336-20342
6. Sohn, J.; Rudolph, J. Catalytic and chemical competence of regulation of cdc25 phosphatase by oxidation/reduction Biochemistry 2003, 42, 10060-10070
7. Arner, E. S.; Holmgren, A. The thioredoxin system in cancer Semin. Cancer Biol. 2006, 16, 420-426
8. Weichsel, A.; Gasdaska, J. R.; Powis, G.; Montfort, W. R. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer Structure 1996, 4, 735-751
9. Holmgren, A.; Soderberg, B. O.; Eklund, H.; Branden, C. I. Three-dimensional structure of Escherichia coli thioredoxin-S2 to 2.8 A resolution Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 2305-2309
10. Forman-Kay, J. D.; Clore, G. M.; Wingfield, P. T.; Gronenborn, A. M. High-resolution three-dimensional structure of reduced recombinant human thioredoxin in solution Biochemistry 1991, 30, 2685-2698
11. Kallis, G. B.; Holmgren, A. Differential reactivity of the functional sulfhydryl groups of cysteine-32 and cysteine-35 present in the reduced form of thioredoxin from Escherichia coli J. Biol. Chem. 1980, 255, 10261-10265
12. Fritz-Wolf, K.; Kehr, S.; Stumpf, M.; Rahlfs, S.; Becker, K. Crystal structure of the human thioredoxin reductase-thioredoxin complex Nat. Commun. 2011, 2, 383
13. Chew, E. H.; Lu, J.; Bradshaw, T. D.; Holmgren, A. Thioredoxin reductase inhibition by antitumor quinols: A quinol pharmacophore effect correlating to antiproliferative activity FASEB J. 2008, 22, 2072-2083
14. Stadtman, E. R.; Moskovitz, J.; Berlett, B. S.; Levine, R. L. Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism Mol. Cell. Biochem. 2002, 234-235, 3-9
15. Das, K. C.; Das, C. K. Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions Biochem. Biophys. Res. Commun. 2000, 277, 443-447
16. Benhar, M.; Forrester, M. T.; Hess, D. T.; Stamler, J. S. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins Science 2008, 320, 1050-1054
17. Saitoh, M.; Nishitoh, H.; Fujii, M.; Takeda, K.; Tobiume, K.; Sawada, Y.; Kawabata, M.; Miyazono, K.; Ichijo, H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1 EMBO J. 1998, 17, 2596-2606
18. Mitchell, D. A.; Morton, S. U.; Fernhoff, N. B.; Marletta, M. A. Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 11609-11614
19. Biaglow, J. E.; Miller, R. A. The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy Cancer Biol. Ther. 2005, 4, 6-13
20. Kakolyris, S.; Giatromanolaki, A.; Koukourakis, M.; Powis, G.; Souglakos, J.; Sivridis, E.; Georgoulias, V.; Gatter, K. C.; Harris, A. L. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer Clin. Cancer Res. 2001, 7, 3087-3091
21. Raffel, J.; Bhattacharyya, A. K.; Gallegos, A.; Cui, H.; Einspahr, J. G.; Alberts, D. S.; Powis, G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival J. Lab. Clin. Med. 2003, 142, 46-51
22. Powis, G.; Kirkpatrick, D. L.; Angulo, M.; Baker, A. Thioredoxin redox control of cell growth and death and the effects of inhibitors Chem.-Biol. Interact. 1998, 111-112, 23-34
23. Welsh, S. J.; Bellamy, W. T.; Briehl, M. M.; Powis, G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis Cancer Res. 2002, 62, 5089-5095
24. Farina, A. R.; Tacconelli, A.; Cappabianca, L.; Masciulli, M. P.; Holmgren, A.; Beckett, G. J.; Gulino, A.; Mackay, A. R. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion Eur. J. Biochem. 2001, 268, 405-413
25. Kim, S. J.; Miyoshi, Y.; Taguchi, T.; Tamaki, Y.; Nakamura, H.; Yodoi, J.; Kato, K.; Noguchi, S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer Clin. Cancer Res. 2005, 11, 8425-8430
26. Wang, J.; Kobayashi, M.; Sakurada, K.; Imamura, M.; Moriuchi, T.; Hosokawa, M. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to adriamycin Blood 1997, 89, 2480-2487
27. Yamada, M.; Tomida, A.; Yoshikawa, H.; Taketani, Y.; Tsuruo, T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines Clin. Cancer Res. 1996, 2, 427-432
28. Yokomizo, A.; Ono, M.; Nanri, H.; Makino, Y.; Ohga, T.; Wada, M.; Okamoto, T.; Yodoi, J.; Kuwano, M.; Kohno, K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide Cancer Res. 1995, 55, 4293-4296
29. Kirkpatrick, D. L.; Kuperus, M.; Dowdeswell, M.; Potier, N.; Donald, L. J.; Kunkel, M.; Berggren, M.; Angulo, M.; Powis, G. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides Biochem. Pharmacol. 1998, 55, 987-994
30. Welsh, S. J.; Williams, R. R.; Birmingham, A.; Newman, D. J.; Kirkpatrick, D. L.; Powis, G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation Mol. Cancer Ther. 2003, 2, 235-243
31. Ramanathan, R. K.; Kirkpatrick, D. L.; Belani, C. P.; Friedland, D.; Green, S. B.; Chow, H. H.; Cordova, C. A.; Stratton, S. P.; Sharlow, E. R.; Baker, A.; Dragovich, T. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors Clin. Cancer Res. 2007, 13, 2109-2114
32. Powis, G.; Wipf, P.; Lynch, S. M.; Birmingham, A.; Kirkpatrick, D. L. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase Mol. Cancer Ther. 2006, 5, 630-636
33. Wipf, P.; Hopkins, T. D.; Jung, J. K.; Rodriguez, S.; Birmingham, A.; Southwick, E. C.; Lazo, J. S.; Powis, G. New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead Bioorg. Med. Chem. Lett. 2001, 11, 2637-2641
34. Rigobello, M. P.; Scutari, G.; Folda, A.; Bindoli, A. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c Biochem. Pharmacol. 2004, 67, 689-696
35. Engman, L.; Al-Maharik, N.; McNaughton, M.; Birmingham, A.; Powis, G. Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants Anticancer Drugs 2003, 14, 153-161
36. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. Elucidation of thioredoxin as a molecular target for antitumor quinols Cancer Res. 2005, 65, 3911-3919
37. Butler, L. M.; Zhou, X.; Xu, W. S.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11700-11705
38. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity J. Biol. Chem. 2005, 280, 25284-25290
39. Wipf, P.; Lynch, S. M.; Birmingham, A.; Tamayo, G.; Jimenez, A.; Campos, N.; Powis, G. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system Org. Biomol. Chem. 2004, 2, 1651-1658
40. Pallis, M.; Bradshaw, T. D.; Westwell, A. D.; Grundy, M.; Stevens, M. F.; Russell, N. Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds Biochem. Pharmacol. 2003, 66, 1695-1705
41. Davioud-Charvet, E.; McLeish, M. J.; Veine, D. M.; Giegel, D.; Arscott, L. D.; Andricopulo, A. D.; Becker, K.; Muller, S.; Schirmer, R. H.; Williams, C. H., Jr.; Kenyon, G. L. Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity Biochemistry 2003, 42, 13319-13330
42. PCT Int. Appl. WO 2000006088 A2 20000210, 2000.
43. Holmgren, A. Reduction of disulfides by thioredoxin. Exceptional reactivity of insulin and suggested functions of thioredoxin in mechanism of hormone action J. Biol. Chem. 1979, 254, 9113-9119
44. Gante, J. Peptidomimetics-Tailored enzyme inhibitors Angew. Chem., Int. Ed. 1994, 33, 1699-1720
45. Mroczkiewicz, M.; Winkler, K.; Nowis, D.; Placha, G.; Golab, J.; Ostaszewski, R. Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach J. Med. Chem. 2010, 53, 1509-1518
46. Ralbovsky, L. J.; Scola, M. P.; Sugino, E.; Burgos-Garcia, C.; Weinreb, M. S.; Parves, M. An attempted total synthesis if lysergic acid via an alkene/N-sulfonylimine cyclization Heterocycles 1996, 43, 1497-1512
47. Obrecht, R.; Herrmann, R.; Ugi, I. Isocyanide synthesis with phosphoryl chloride and diisopropylamine Synthesis 1985, 4, 400-402
48. Mitra, S.; Lawton, R. G. Reagents for the crosslinking of proteins by equilibrium transfer alkylation J. Am. Chem. Soc. 1979, 101, 3097-3110
49. Greef de, M.; Abeln, S.; Belkasmi, K.; Dömling, A.; Orru, V. A. R.; Wessjohann, A. L. Rapid combinatorial access to macrocyclic ansapeptoids and ansapeptides with natural-product-like core structures Synthesis 2006, 23, 3997-4004
50. Wagner, B. M.; Smith, R. A.; Coles, P. J.; Copp, L. J.; Ernest, M. J.; Krantz, A. In vivo inhibition of cathepsin B by peptidyl (acyloxy)methyl ketones J. Med. Chem. 1994, 37, 1833-1840
51. Kirkpatrick, D. L.; Jimale, M. L.; King, K. M.; Chen, T. Synthesis and evaluation of imidazolyl disulfides for selective cytotoxicity to hypoxic EMT6 tumor cells in vitro Eur. J. Med. Chem. 1992, 27, 33-37
52. Filipek, R.; Rzychon, M.; Oleksy, A.; Gruca, M.; Dubin, A.; Potempa, J.; Bochtler, M. The Staphostatin-staphopain complex: A forward binding inhibitor in complex with its target cysteine protease J. Biol. Chem. 2003, 278, 40959-40966